ArticleInfection and immunity2006
Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.
Article in Infection and immunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Ultrastructural Study ofFrontiers in microbiology · 2021Article
- Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells.Infection and immunity · 2019Article
- Cryptococcus neoformans: Tripping on Acid in the Phagolysosome.Frontiers in microbiology · 2016Review
- Immunity to Cryptococcus neoformans and C. gattii during cryptococcosis.Fungal genetics and biology : FG & B · 2015Review
- The Cryptococcus neoformans capsule: lessons from the use of optical tweezers and other biophysical tools.Frontiers in microbiology · 2015Review
- Host immunity to Cryptococcus neoformans.Future microbiology · 2015Review
- Cryptococcus inositol utilization modulates the host protective immune response during brain infection.Cell communication and signaling : CCS · 2014Article
- Allergen1 regulates polysaccharide structure in Cryptococcus neoformans.Molecular microbiology · 2013Article
- Article
- Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans.Infection and immunity · 2011Article
- Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformans.Frontiers in microbiology · 2011Article
- Cryptococcal interactions with the host immune system.Eukaryotic cell · 2010Review
- Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.Molecular microbiology · 2009Article
- The capsule of the fungal pathogen Cryptococcus neoformans.Advances in applied microbiology · 2009Review
- How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans.Annual review of microbiology · 2009Review
- Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.Infection and immunity · 2007Article
- Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.Infection and immunity · 2006Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
The polysaccharide capsule of Cryptococcus neoformans is a powerful activator of the complement system. The goal of the present study was to assess serum and cellular variables that influence the sites for C3 binding within the capsular matrix. Confocal microscopy using fluorophore-labeled polyclonal anti-C3 and anticapsular monoclonal antibodies and rosetting of fluorescent microspheres coated with anti-C3 were used to identify sites of C3 binding relative to the capsular edge. The results showed that the source of serum was a major variable influencing localization of C3. C3 bound at or very near the capsular edge in the case of human serum. C3 deposition was further from the capsule edge with guinea pig and rat sera; in the case of mouse serum, there was no binding of C3 in the outer region of the capsule. Addition of human C3 to mouse serum led to deposition of the C3 at the capsular edge, indicating that distinct properties of mouse and human C3 account for the differential localization of C3. Finally, the density of the capsular matrix was an important variable in determining sites for C3 deposition. Yeast cells with a high concentration of polysaccharide near the capsule edge supported deposition of mouse C3 at or near the capsular edge, whereas cells with a low matrix density showed deposition well beneath the edge. Taken together, these results indicate that the spatial deposition of C3 within the capsular matrix is a complex process that is influenced by the serum source and the density of the capsular matrix.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.